Home Diabetes Care Tandem’s Mobi Approved by the FDA

Tandem’s Mobi Approved by the FDA

0
Tandem’s Mobi Approved by the FDA

 

On Tuesday, July eleventh, 2023, the Food and Drug Administration (FDA) announced the approval of Tandem’s newest insulin pump, called Mobi. This insulin pump is fully controllable from a mobile app and is now the world’s smallest durable automated insulin delivery system. 

The Mobi insulin pump

The Mobi will join a growing collection of Tandem products that support individuals with diabetes. Their human-centered approach to design, develop and support revolutionary services for individuals who use insulin is clear on this latest approval.

John Sheridan, president and chief executive officer for Tandem Diabetes Care said, “Through this expansion, we’re delivering on our commitment to bring greater selection, together with the proven advantages of Tandem’s technology, to more people living with diabetes.” 

The San Diego-based company also manufactures the T:Slim X2 insulin pump with Control-IQ technology, a feature that can be a part of this latest release.

Control-IQ technology utilizes compatible continuous glucose monitor (CGM) sensor readings to predict blood sugar levels half-hour ahead of time. It then adjusts insulin delivery every five minutes to assist prevent each high and low blood sugars levels. The system also delivers automatic correction boluses of insulin for as much as an hour to assist prevent high blood sugars. 

The user can still manually bolus for snacks and meals. 

The Mobi has been approved for individuals with diabetes aged six and older who require insulin. 

Mobi features 

The brand new Mobi has some great features that may make pumping not only easier for people, but more convenient and versatile too. 

  • 200-unit insulin cartridge 
  • Lower than half the dimensions of the T:Slim X2 pump
  • Detachable infusion sets which can be compatible with all existing Tandem infusion sets, allowing users to combine and match infusion sites and tubing length combos for greater flexibility
  • Control IQ technology designed to be used as a part of an automatic insulin delivery system 
  • Mobile app control with an on-pump button, providing an option for the user to utilize phone control for bolusing insulin 
  • Inductive charging and able to wireless distant software updates from a compatible smartphone

More selections for individuals with diabetes 

This latest approval will greatly expand the alternatives individuals with diabetes who use insulin pumps may have, and it’s the smallest and most convenient insulin pump yet. 

Based on the manufacturer, the Mobi is sufficiently small to slot in a coin pocket, be clipped to clothing or fit into an adhesive sleeve—expanding where and the way and insulin pump matches into your life and lifestyle.

Moreover, the Mobi insulin pump is totally controllable from a user’s cell phone via an app, a feature many individuals with diabetes are on the lookout for in newer tech releases. 

People don’t wish to all the time be juggling multiple devices, and having each blood sugar readings and insulin pumping capability from a smartphone just makes life with diabetes easier. 

Market availability coming soon 

A limited release is predicted to begin in late 2023 with full business release planned for early 2024. To join updates, please visit tandemdiabetes.com/mobi. 

For those who are interested by trying the Mobi insulin pump when it is out there, start talking to your provider now about any essential steps chances are you’ll must take like getting a prior authorization

LEAVE A REPLY

Please enter your comment!
Please enter your name here